THLD Share Price

Open 0.45 Change Price %
High 0.46 1 Day 0.00 0.00
Low 0.43 1 Week -0.02 -4.17
Close 0.46 1 Month 0.08 21.05
Volume 569035 1 Year -0.15 -24.59
52 Week High 1.48
52 Week Low 0.21
THLD Important Levels
Resistance 2 0.49
Resistance 1 0.48
Pivot 0.45
Support 1 0.44
Support 2 0.43
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
QKLS 0.12 -36.84%
More..

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)

THLD Technical Analysis 4
As on 7th Dec 2016 THLD Share Price closed @ 0.46 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.53 & Strong Sell for SHORT-TERM with Stoploss of 0.56 we also expect STOCK to react on Following IMPORTANT LEVELS.
THLD Target for December
1st Target up-side 0.61
2nd Target up-side 0.7
3rd Target up-side 0.79
1st Target down-side 0.35
2nd Target down-side 0.26
3rd Target down-side 0.17
THLD Other Details
Segment EQ
Market Capital 230068016.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.thresholdpharm.com
THLD Address
THLD
170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
Phone: 650-474-8200
Fax: 650-474-2529
Interactive Technical Analysis Chart Threshold Pharmaceuticals, Inc. ( THLD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Threshold Pharmaceuticals, Inc.
THLD Business Profile
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors and the bone marrows of some hematologic malignancies (blood cancers) as treatments for patients living with cancer. The Company's hypoxia activated prodrug product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. The Company's focus is on product candidates for the treatment of patients with cancer. The Company's clinical development efforts are focused on TH-302, for which the Company entered a license and co-development agreement with Merck KGaA, on February 2, 2012, for worldwide development and commercialization. As of December 31, 2011, TH-302 is in Phase I, Phase II and Phase III clinical trials. The Company reported updated results from the Phase I monotherapy trial of TH-302.